Targeting TRPV2 could affect the signaling pathways associated with LBCs growth/proliferation and chemotaxis/infiltration processes, prompting the evaluation of TRPV2 as a promising pharmacodynamic biomarker especially in the setting of aggressive stages of leukemia that might be associated with high risk of [lung] hyperinflammation due to LBCs infiltration. This evidence concerns the gene TRPV2 and leukemia.